ClinicalTrials.gg
CompletedNCT03290027DFD-03Updated Mar 1, 2021Results posted

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

A Phase 3 interventional study of DFD-03 and Placebo Comparator in Acne Vulgaris, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2021-03-01.

Sponsored by Dr. Reddy's Laboratories Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 374 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
67th of 354
550 · median 78
Started
2017
with 22 others
Phase 3
76 of 374
1 open now
Registered
235th of 374
by date

Among the 374 studies in Acne Vulgaris with a site in United States, this one is the 67th largest by enrollment of the 354 interventional ones that give a count, is one of 23 that started in 2017, is one of 76 in phase 3, and was the 235th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 374 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

Enrollment of subjects with mild to moderate facial acne. Efficacy was assessed by using an Investigator's Global Assessment scale (IGA 5 point scale) and by counting the number of inflammatory and non-inflammatory lesions on the face at Baseline and Weeks 4, 8, and 12.

Safety assessments included the investigator's assessment of local cutaneous tolerance of the treated skin (dryness, non-lesional erythema, peeling, stinging, burning, and itching, vital signs, and adverse events (AEs).

Read the detailed description

Enrollment of subjects with mild to moderate facial acne. Subjects with acne lesions of any severity on the chest and/or back (including shoulders) were enrolled provided they had mild to moderate acne on the face. During the 12-week treatment period subjects used the study product twice daily. Subjects were instructed to treat the entire face (and chest and/or back including shoulders, if applicable).

Efficacy was assessed by using an Investigator's Global Assessment scale (IGA 5 point scale) and by counting the number of inflammatory and non-inflammatory lesions on the face at Baseline and Weeks 4, 8, and 12.

Safety assessments included the investigator's assessment of local cutaneous tolerance of the treated skin (dryness, non-lesional erythema, peeling, stinging, burning, and itching; assessed separately on the chest and/or back including shoulders (if applicable), vital signs (blood pressure and pulse rate), and adverse events (AEs). Urine pregnancy tests were performed at Baseline and at every visit through Week 12 for all female subjects. A physical examination was performed.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Subject must be at least 9 years of age.
  2. A clinical diagnosis of mild to moderate facial acne vulgaris.
  3. Inflammatory lesion count (papules and pustules) of at least 20 on the face, Non-inflammatory lesion count (closed and open comedones) of at least 25 on the face and No more than 2 nodulocystic lesions on the face.
  4. Females, regardless of , if sexually active, must be on or use an acceptable method of .
  5. Subject must be in good general health as determined by the investigator and supported by medical history, physical and Vital Signs exam.

Main Exclusion Criteria:

  1. Females who are pregnant or lactating or planning to become pregnant.
  2. Treatment with the following products:

    1. Topical acne treatments or other topical facial medication on the treatment area.
    2. Systemic , systemic acne treatments including systemic antibiotics used for treatment of acne.
    3. Systemic retinoid use.
    4. Undertaken certain facial procedures such as chemical peel, laser treatment, photodynamic therapy, acne surgery, cryodestruction or chemodestruction, x-ray therapy, intralesional steroids, dermabrasion, or depilation (except eyebrow shaping).
    5. Treatment with a medication or procedure that, in the opinion of the investigator, would put the subject at unacceptable risk for participation in the study or may interfere with evaluations in the study.
    6. Treatment with an product or device in the 30 days.
  3. Known allergic reaction to retinoids or tazarotene.
  4. Presence of any facial skin disease or condition that would interfere with the study or place the subject at unacceptable risk including sunburn, rosacea, seborrheic dermatitis, perioral dermatitis, lupus, dermatomyositis, psoriasis, eczema, squamous cell carcinoma, acneiform eruptions caused by medications, steroid acne, steroid folliculitis, bacterial folliculitis or any other facial disease or condition.
  5. Subjects with a serious and/or chronic medical condition such as chronic or active liver disease, renal impairment, heart disease, severe respiratory disease, rheumatoid arthritis, current , conditions, or any other disease that, in the opinion of the investigator, would interfere with the study or place the subject at unacceptable risk.
  6. Subjects who have been in another investigational trial within 30 days.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
550 participants (actual)

Study arms

  • Experimental
    Active

    DFD-03 (0.1% tazarotene) Lotion

    Drug: DFD-03

  • Placebo comparator
    Vehicle

    Vehicle (0% tazarotene) Lotion

    Other: Placebo Comparator

Interventions

  • DrugDFD-03

    DFD-03 Lotion

    Also known as: Tazarotene 0.1% Lotion

  • OtherPlacebo Comparator

    Vehicle (tazarotene 0%) Lotion

    Also known as: Vehicle

06

What researchers measure

Primary outcomes

  1. Absolute Change in the Inflammatory Lesion Counts on the Face

    Change in inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using a two way analysis of covariance (ANCOVA) model

    Time frame: Baseline to Week 12

  2. Absolute Change in the Non-inflammatory Lesion Counts on the Face

    Change in non-inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using the same ANCOVA model

    Time frame: Baseline to Week 12

  3. Proportion of Subjects With Treatment Success Based on IGA Score

    IGA success at Week 12 (an IGA score of 0 (Clear) or 1 (almost clear) with at least a 2-grade reduction from baseline) - will be analyzed using the Cochran-Mantel-Haenszel (CMH) test for general association

    Time frame: Baseline to Week 12

07

Results

Posted May 26, 2020

Participant flow

Participant flow — Overall Study
MilestoneActiveVehicle
Started277273
Completed219228
Not completed5845

Outcome measures

PrimaryAbsolute Change in the Inflammatory Lesion Counts on the Face

Change in inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using a two way analysis of covariance (ANCOVA) model

Time frame:
Baseline to Week 12
Reported as:
Mean · Lesions
Absolute Change in the Inflammatory Lesion Counts on the Face
LesionsActiveVehicle
Baseline30.1 ± 9.8129.8 ± 9.13
Week 1215.4 ± 11.4316.9 ± 11.78
PrimaryAbsolute Change in the Non-inflammatory Lesion Counts on the Face

Change in non-inflammatory lesion counts on the face from baseline to Week 12 - will be analyzed using the same ANCOVA model

Time frame:
Baseline to Week 12
Reported as:
Mean · Lesions
Absolute Change in the Non-inflammatory Lesion Counts on the Face
LesionsActiveVehicle
Baseline37.4 ± 14.7136.6 ± 13.07
Week 1220.3 ± 13.8822.1 ± 18.26
PrimaryProportion of Subjects With Treatment Success Based on IGA Score

IGA success at Week 12 (an IGA score of 0 (Clear) or 1 (almost clear) with at least a 2-grade reduction from baseline) - will be analyzed using the Cochran-Mantel-Haenszel (CMH) test for general association

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Proportion of Subjects With Treatment Success Based on IGA Score
ParticipantsActiveVehicle
Proportion of Subjects With Treatment Success Based on IGA Score5134

Adverse events

Collected over Adverse event data were collected from the time treatment was initiated until study product treatment was discontinued, except for spontaneously reported SAEs, which were to be reported up to 30 days after discontinuing study product use.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active0/277 (0%)2/277 (0.7%)0/277 (0%)
Vehicle0/273 (0%)1/273 (0.4%)0/273 (0%)
Most frequent serious events
Most frequent serious events
EventActiveVehicle
Overian cyst rupturedReproductive system and breast disorders0/2771/273
AnxietyPsychiatric disorders1/2770/273
Polyps/EpithelioidNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2770/273

Baseline characteristics

Intent to Treat (ITT) - The ITT population was the primary efficacy analysis data set and consisted of all subjects who were randomized and dispensed study medication.

Age, Categorical
Age, Categorical(Participants)ActiveVehicleTotal
<=18 years9191182
Between 18 and 65 years186182368
>=65 years000
Age, Continuous
Age, Continuous(years)ActiveVehicleTotal
Mean21.2 ± 7.921.1 ± 8.021.2 ± 7.9
Sex: Female, Male
Sex: Female, Male(Participants)ActiveVehicleTotal
Female145158303
Male132115247
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ActiveVehicleTotal
Hispanic or Latino109105214
Not Hispanic or Latino168168336
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ActiveVehicleTotal
American Indian or Alaska Native011
Asian14721
Native Hawaiian or Other Pacific Islander000
Black or African American5158109
White200194394
More than one race000
Unknown or Not Reported121325
Region of Enrollment
Region of Enrollment(Participants)ActiveVehicleTotal
United States277273550
08

Study locations

1 site
  • Dr. Seemal
    Plano, Texas 75024, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Apr 2018, 8 months.

Results were first posted in May 2020, 2 years 1 month after primary completion. A results delay was requested in Sep 2019.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 8 months is below that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 21, 2017
StartActual
Jul 31, 2017
Primary completionActual
Apr 19, 2018
CompletionActual
Apr 19, 2018
Results delay requested
Sep 24, 2019
Results first posted
May 26, 2020
Last update
Mar 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03290027
Responsible party
Sponsor
First posted
Sep 21, 2017
Start date
Jul 31, 2017
Primary completion
Apr 19, 2018
Completion
Apr 19, 2018
Results posted
May 26, 2020
Last update
Mar 1, 2021

Study contacts

Srinivas Sidgiddi, M.D.
study director · Dr. Reddy's Laboratories Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion